AcuCort AB (publ) announced that the Danish Medicines Agency, Laegemiddelstyrelsen, has approved the company's first drug under the name Zeqmelit in Denmark. The same drug is already approved in Sweden, but under the brand name ISICORT®. In the development of the drug Zeqmelit/ISICORT®, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick accessibility and relief in acute situations such as severe and acute allergic reactions.

The registration process for the Nordic market is ongoing and the drug is now approved in Denmark and Sweden. Intensive work is underway on registration applications for other priority markets. AcuCort's goal is to commercialize Zeqmelit/ISICORT® globally, i.e. in the EU, the US and in selected key markets.